Severe Persistent Asthma
FDA approves omalizumab biosimilar Omlyclo
The FDA approved Celltrion’s omalizumab biosimilar, Omlyclo, for the treatment of multiple conditions including asthma and food allergy, according to an agency press release.
Impacts of severe persistent asthma vary across US
The prevalence of severe persistent asthma among patients with asthma significantly ranges across the United States, from 19.6% in New Mexico to 31.9% in Alaska, according to a study published in Annals of Allergy, Asthma & Immunology.
Q&A: Rademikibart may be ‘transformational therapy’ for moderate to severe asthma
Topline results from a phase 2b trial revealed that rademikibart led to improvements in lung function and asthma control in adults with moderate to severe persistent asthma compared with placebo.
Long-term azithromycin increases lumen radius, area in severe persistent asthma
Long-term azithromycin treatment increased lumen radius and lumen area in patients with severe persistent asthma, but did not affect bronchial wall thickness, according to new data published in Respiratory Medicine.